23andMe Stock

23andme.comHealthcareFounded: 2006Funding to Date: $791.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

23andMe investors also invested in these private companies

Team

Management Team

Anne Wojcicki
CEO & Co-Founder
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Steve Schoch
CFO
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Mike Polcari
Vice President & Chief Architect
Fred Kohler
Vice President, People

Board Members

Anne Wojcicki
23andMe
Patrick Chung
Xfund
Neal Mohan
23andMe
Roelof Botha
Sequoia Capital
Richard Scheller, Ph.D.
Self

Other companies like 23andMe in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$453MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$355.29MM
Sector
Last Round Est. Valuation
$8.18B
Sector
Last Round Est. Valuation
$263MM
Sector
Last Round Est. Valuation
$67.5MM

News

23andMe went public through a merger with a special purpose acquisition vehicle in June.
23andMe is one of our favorite DNA kits — and it's currently half off as part of Amazon Prime Day 2021, which ends on June 22.
The future of consumer genomics lies in healthcare partnerships and drug development, according to a new CB Insights report released last week.